Physician profile
Steven John Voiles
NPI 1013902097
$1,119.09
in general payments reported to CMS, 2019-2025
14 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.56 · 2021: $14.40 · 2022: $176 · 2023: $213 · 2024: $209 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.14 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $145.11 | 2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $135.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Abbott Laboratories | $119.25 | 2024-2025 | Mitraclip, Freestyle Libre 3 |
| Dexcom, INC. | $118.10 | 2024 | Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $113.97 | 2022-2023 | Arexvy |
| Exact Sciences Corporation | $57.83 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $40.46 | 2025 | Veozah |
| Abbvie INC. | $35.36 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $19.25 | 2024 | |
| Pfizer INC. | $18.60 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.56 | 2019 | |
| Axsome Therapeutics, INC. | $14.75 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Voiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.